Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alector, Inc.ALEC · Entity 6051 | President and Head of R&D | December 03, 2025 | December 04, 2025 |
| Unicycive Therapeutics, Inc.UNCY · Entity 6568 | Director | May 14, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alector, Inc.
Report date December 03, 2025 · Filed December 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 501,652 |
Reported balance
After 2025-12-03 transaction · row 1
1 source rowRow 1 · 2025-12-03 · Sale · Disposed 41,687 · Balance 501,652 F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.095 to $1.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.095 to $1.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request.
Unicycive Therapeutics, Inc.
Report date May 14, 2026 · Filed July 28, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 47,941 |
Reported balance
After 2026-05-14 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 47,941 · Balance 47,941 F1: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 21, 2026 20:30 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Units · Derivative | 42,100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060079 · ownership.xml · derivative · entry 2 Kenkare-Mitra Sara · CIK 0001895592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,300 Underlying: Common Stock · 42,100 shares Expires not disclosed F2 · derivative.exercise_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer. F2 · derivative.expiration_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed May 21, 2026 20:30 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Units · Derivative | 84,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060079 · ownership.xml · derivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,200 Underlying: Common Stock · 84,200 shares Expires not disclosed F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed Jun 15, 2026 21:24 UTC Amendment | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Units · Derivative | 42,100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-068921 · ownership.xml · derivative · entry 2 Kenkare-Mitra Sara · CIK 0001895592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,300 Underlying: Common Stock · 42,100 shares Expires not disclosed F2 · derivative.exercise_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. F2 · derivative.expiration_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed Jun 15, 2026 21:24 UTC Amendment | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Units · Derivative | 84,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-068921 · ownership.xml · derivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,200 Underlying: Common Stock · 84,200 shares Expires not disclosed F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed Jul 28, 2026 20:15 UTC Amendment | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Units · Derivative | 47,941 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-082273 · ownership.xml · derivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,941 Underlying: Common Stock · 47,941 shares Expires not disclosed F1 · derivative.exercise_date: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 02:05 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 41,687 | $1.12 | $46,672.77 |
DisclosureSEC source: 0001895592-25-000005 · form4-12042025_021236.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,652 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.095 to $1.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:29 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 23,638 | $2.50 | $59,019.36 |
DisclosureSEC source: 0001415889-25-023674 · form4-09042025_080906.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,339 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.30 to $2.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:30 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 21,200 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001213900-25-069304 · ownership.xml · derivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,200 Underlying: Common Stock · 21,200 shares Expires 2035-07-28 Read SEC document |
| July 01, 2025 Filed Jul 1, 2025 21:00 UTC | Alector, Inc. ALEC · Entity 6051 | GrantEmployee Stock Option (right to buy) · Derivative | 18,250 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0000950170-25-092313 · ownership.xml · derivative · entry 2 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock · 18,250 shares Expires 2035-07-01 F2 · derivative.exercise_date: One third (1/3rd) of the total shares subject to the option shall vest on November 1, 2025, and one twelfth (1/12th) of the total shares subject to the option shall vest in equal monthly installments thereafter, provided that the shares subject to the option will vest in full on July 1, 2026. Read SEC document |
| July 01, 2025 Filed Jul 1, 2025 21:00 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 54,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-092313 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 566,977 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, one half (1/2) of the total shares shall vest on December 1, 2025 and one fourth (1/4th) of the total shares shall vest quarterly thereafter. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:19 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 23,890 | $1.34 | $31,974.38 |
DisclosureSEC source: 0001415889-25-015585 · form4-06042025_080634.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,252 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.285 to $1.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 29,073 | $1.47 | $42,661.72 |
DisclosureSEC source: 0000950170-25-033534 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,142 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.4673 to $1.4676. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 22:40 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 26,500 | $2.52 | $66,764.10 |
DisclosureSEC source: 0000950170-24-132911 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,215 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.5193 to $2.5194. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-111422 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 591,715 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on December 1, 2024. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:15 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 13,926 | $4.88 | $67,981.16 |
DisclosureSEC source: 0000950170-24-103407 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,715 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.8815 to $4.8818. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 22:05 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 13,206 | $4.80 | $63,372.95 |
DisclosureSEC source: 0000950170-24-068938 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,641 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.7987 to $4.7988. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 23:00 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,169 | $6.92 | $70,386.77 |
DisclosureSEC source: 0000950170-24-026428 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,847 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.9217 to $6.9218. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 23:30 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 12,519 | $5.56 | $69,605.64 |
DisclosureSEC source: 0000950170-23-068616 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,016 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 22:10 UTC | Alector, Inc. ALEC · Entity 6051 | GrantEmployee Stock Option (right to buy) · Derivative | 54,500 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0000950170-23-051703 · ownership.xml · derivative · entry 2 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,500 Underlying: Common Stock · 54,500 shares Expires 2033-10-01 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on November 1, 2023. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 22:10 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 163,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-051703 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,535 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on December 1, 2023. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 23:17 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 6,214 | $5.19 | $32,277.38 |
DisclosureSEC source: 0000950170-23-046835 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,935 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 20:33 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 180,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001213900-23-075012 · ownership.xml · derivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2033-09-05 Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 22:54 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 4,092 | $6.90 | $28,249.94 |
DisclosureSEC source: 0000950170-23-026481 · ownership.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,149 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 01:53 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,124 | $8.32 | $84,216.49 |
DisclosureSEC source: 0001209191-23-016087 · doc4.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,241 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 23:22 UTC | Alector, Inc. ALEC · Entity 6051 | GrantEmployee Stock Option (right to buy) · Derivative | 53,576 | $0.00 Strike: $9.46 | $0.00 |
DisclosureSEC source: 0001209191-22-052532 · doc4.xml · derivative · entry 2 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,576 Underlying: Common Stock · 53,576 shares Expires 2032-10-01 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on November 1, 2022. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 23:22 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 80,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052532 · doc4.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,365 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on March 1, 2023. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:08 UTC | Alector, Inc. ALEC · Entity 6051 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $20.78 | $0.00 |
DisclosureSEC source: 0001209191-22-001791 · doc4.xml · derivative · entry 3 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the option shall vest on December 15, 2022 and one forty-eighth of the shares vest monthly thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:08 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 59,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001791 · doc4.xml · nonDerivative · entry 2 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 F2 · shares: Shares consist of performance share units, or PSUs, which vest as follows: twenty-five percent of the award will be earned if, within four years of January 3, 2022, the Issuer's average closing stock price is $30 per share for 40 consecutive trading days and the remaining seventy-five percent will be earned if the average closing stock price is $40 per share for 40 consecutive trading days. Upon attainment of the performance metrics, the shares vest in four equal quarterly installments beginning on the first vesting date as set forth in the PSU award agreement. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:08 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 59,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001791 · doc4.xml · nonDerivative · entry 1 Kenkare-Mitra Sara · CIK 0001895592 · President and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 F1 · shares: Shares consist of restricted stock units, or RSUs, which vest as follows: one-third of the RSUs vest on March 1, 2023 and one-twelfth of the RSUs vest quarterly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.